The first and only VMAT2 inhibitor approved for both TD and HD chorea1

Before you prescribed AUSTEDO for his tardive dyskinesia (TD), he was concerned about people noticing his movements.1

Now expressing
himself is
what moves him

Man and son enjoying ice cream cones on park bench. “Now expressing himself is what moves him” written next to them.
 Man and son enjoying ice cream cones on park bench. “Now expressing himself is what moves him” written next to them.

Purple video icon.

Mechanism of Action:

VMAT2 inhibition can help regulate dopamine function.4

AIMS, Abnormal Involuntary Movement Scale; HD, Huntington’s disease; VMAT2, vesicular monoamine transporter 2.

REFERENCES: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 2. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. 3. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment is associated with continued improvement in tardive dyskinesia in the completed 3-year open-label extension study. Presented at: the 26th National Psychopharmacology Update Virtual Meeting; February 10-13, 2021. 4. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215-1238.